IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
14.6%
Sector: -43.5%
Dividend Analysis audit
GROWTH
0.14%
Trailing Yield
$0.14
Per $100 Invested
Modest dividend — capital prioritized for reinvestment.
Est. Payout Ratio
5%SAFE
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, ENSIGN GROUP, INC (ENSG) receives a "Hold" rating with a composite score of 51.7/100, ranked #340 out of 4446 stocks. Key factor scores: Quality 50/100, Value 54/100, Momentum 63/100. This is quantitative analysis only — not investment advice.
ENSIGN GROUP, INC (ENSG) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ENSIGN GROUP, INC Do?
The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company operates in two segments, Skilled Services and Real Estate. The company offers skilled services, which include short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; and physical, occupational, and speech therapies and other rehabilitative and healthcare services. It also provides standard services, such as room and board, special nutritional programs, social, recreational, entertainment, and other services. In addition, the company offers senior living, as well as mobile diagnostics services; leases real estate properties; and provides other ancillary services consisting of digital x-ray, ultrasound, electrocardiogram, laboratory, sub-acute, and patient transportation services to people in their homes or at long-term care facilities. As of April 4, 2022, it operated 252 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California. ENSIGN GROUP, INC (ENSG) is classified as a large-cap stock in the Healthcare sector. The company is led by CEO Barry R. Port and employs approximately 29,900 people, headquartered in Dover, California. With a market capitalization of $11.6B, ENSG is one of the prominent companies in the Healthcare sector.
ENSIGN GROUP, INC (ENSG) Stock Rating — Hold (April 2026)
As of April 2026, ENSIGN GROUP, INC receives a Hold rating with a composite score of 51.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ENSG ranks #340 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ENSIGN GROUP, INC ranks #15 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ENSG Stock Price and 52-Week Range
ENSIGN GROUP, INC (ENSG) currently trades at $201.56. The 52-week high for ENSG is $216.92, which means the stock is currently trading -7.1% from its annual peak. The 52-week low is $118.73, putting the stock 69.8% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is ENSG Overvalued or Undervalued? — Valuation Analysis
ENSIGN GROUP, INC (ENSG) carries a value factor score of 54/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 35.76x, compared to the Healthcare sector average of 23.63x — a premium of 51%. The price-to-book ratio stands at 5.24x, versus the sector average of 2.75x. The price-to-sales ratio is 2.45x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ENSG trades at 30.32x EV/EBITDA, versus 6.34x for the sector.
Overall, ENSG's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
ENSIGN GROUP, INC Profitability — ROE, Margins, and Quality Score
ENSIGN GROUP, INC (ENSG) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 14.6%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 6.0% versus the sector average of -33.1%.
On a margin basis, ENSIGN GROUP, INC reports gross margins of 20.4%, compared to 71.5% for the sector. The operating margin is 8.2% (sector: -66.1%). Net profit margin stands at 6.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 25.1% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
ENSG Debt, Balance Sheet, and Financial Health
ENSIGN GROUP, INC has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.42x, suggesting adequate working capital coverage. Total debt on the balance sheet is $144M. Cash and equivalents stand at $444M.
ENSG has a beta of 0.44, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ENSIGN GROUP, INC is 88/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
ENSIGN GROUP, INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, ENSIGN GROUP, INC reported revenue of $4.78B and earnings per share (EPS) of $6.00. Net income for the quarter was $327M. Gross margin was 20.4%. Operating income came in at $391M.
In FY 2025, ENSIGN GROUP, INC reported revenue of $5.06B and earnings per share (EPS) of $6.00. Net income for the quarter was $344M. Gross margin was 20.5%. Revenue grew 18.7% year-over-year compared to FY 2024. Operating income came in at $425M.
In Q3 2025, ENSIGN GROUP, INC reported revenue of $1.30B and earnings per share (EPS) of $1.46. Net income for the quarter was $84M. Gross margin was 19.4%. Revenue grew 19.8% year-over-year compared to Q3 2024. Operating income came in at $96M.
In Q2 2025, ENSIGN GROUP, INC reported revenue of $1.23B and earnings per share (EPS) of $1.48. Net income for the quarter was $84M. Gross margin was 20.8%. Revenue grew 18.5% year-over-year compared to Q2 2024. Operating income came in at $104M.
Over the past 8 quarters, ENSIGN GROUP, INC has demonstrated a growth trajectory, with revenue expanding from $1.04B to $4.78B. Investors analyzing ENSG stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ENSG Dividend Yield and Income Analysis
ENSIGN GROUP, INC (ENSG) currently pays a dividend yield of 0.1%. At this yield, a $10,000 investment in ENSG stock would generate approximately $$14.00 in annual dividend income. The net margin of 6.9% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.
ENSG Momentum and Technical Analysis Profile
ENSIGN GROUP, INC (ENSG) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ENSG vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing ENSG against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ENSG vs S&P 500 (SPY) comparison to assess how ENSIGN GROUP, INC stacks up against the broader market across all factor dimensions.
ENSG Next Earnings Date
No upcoming earnings date has been announced for ENSIGN GROUP, INC (ENSG) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ENSG? — Investment Thesis Summary
ENSIGN GROUP, INC presents a balanced picture with arguments on both sides. Price momentum is positive at 63/100, suggesting the trend favors buyers. Low volatility (stability score 88/100) reduces downside risk.
In summary, ENSIGN GROUP, INC (ENSG) earns a Hold rating with a composite score of 51.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ENSG stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
ENSIGN GROUP, INC (ENSG) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
We maintain a Hold rating on Ensign Group (ENSG), driven by a balanced view of its strong operational performance and aggressive growth strategy offset by valuation concerns and inherent risks within the skilled nursing facility (SNF) industry. While ENSG has demonstrated impressive revenue growth and profitability improvements, its current valuation appears stretched relative to peers and historical averages, limiting potential upside. The company's reliance on acquisitions for growth also introduces integration and operational risks that warrant caution.
Our analysis suggests that ENSG's operational efficiency and focus on higher-acuity patients provide a competitive edge, but the industry's regulatory landscape and reimbursement pressures pose significant challenges. The Hold rating reflects our belief that ENSG's future performance will likely be in line with the broader market, with limited opportunities for outperformance given the current risk-reward profile. Investors should closely monitor the company's ability to maintain its growth trajectory while navigating the complexities of the healthcare sector.
Business Strategy & Overview
Ensign Group operates within the post-acute care continuum, primarily focusing on skilled nursing facilities (SNFs). The company generates revenue through a combination of government reimbursements (Medicare and Medicaid) and private pay sources. ENSG's core strategy revolves around acquiring underperforming SNFs, implementing its proprietary operational model to improve efficiency and patient outcomes, and ultimately increasing profitability. This model, often referred to as a 'turnaround' strategy, is central to their growth.
A key component of ENSG's strategy is its decentralized management structure, which empowers local leaders to make operational decisions tailored to their specific facilities and patient populations. This approach aims to foster a culture of accountability and innovation, leading to improved clinical outcomes and cost management. The company also invests in training and development programs for its staff, emphasizing quality of care and patient satisfaction.
Beyond SNFs, ENSG has expanded into ancillary businesses, including senior living, mobile diagnostics, and real estate. These ventures provide diversification and potential synergies with its core SNF operations. The company's real estate segment involves leasing properties to its own facilities and third-party operators, generating a stable stream of rental income. The mobile diagnostics services offer convenient and cost-effective diagnostic testing for patients in their homes or long-term care facilities.
The healthcare industry is characterized by intense competition and evolving regulatory requirements. ENSG competes with other SNF operators, hospitals, and home healthcare providers. The company's success depends on its ability to attract and retain patients, manage costs effectively, and comply with complex regulations. Reimbursement rates from government payers are a critical factor influencing ENSG's profitability, and changes in these rates can significantly impact its financial performance. The company's strategic focus on higher-acuity patients, who require more specialized care, allows them to command higher reimbursement rates compared to standard SNF services.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
25.1%
Sector: 10.6%
+136% VS SCTR
Economic Moat Analysis
Ensign Group possesses a Narrow economic moat, primarily derived from its operational expertise and efficient scale within the fragmented skilled nursing facility (SNF) industry. The company's proven ability to acquire and turn around underperforming facilities creates a barrier to entry for competitors lacking similar operational capabilities. This expertise allows ENSG to extract value from assets that others may overlook, generating superior returns on investment.
The SNF industry is highly fragmented, with numerous small and independent operators. This fragmentation provides ENSG with ample opportunities to acquire facilities at attractive prices. The company's efficient scale enables it to spread fixed costs across a larger base of operations, resulting in lower operating expenses per facility compared to smaller competitors. This cost advantage contributes to ENSG's profitability and competitive positioning.
However, the moat is considered narrow due to several factors. The SNF industry is subject to intense regulatory scrutiny and reimbursement pressures, which can erode profitability and limit pricing power. Government payers, such as Medicare and Medicaid, exert significant influence over reimbursement rates, and changes in these rates can have a material impact on ENSG's financial performance. The company's reliance on acquisitions for growth also introduces integration risks, as not all acquisitions may be successful in achieving the desired operational improvements.
Furthermore, the SNF industry is characterized by relatively low switching costs for patients and referral sources. Patients can easily transfer to other facilities if they are dissatisfied with the quality of care or service. Referral sources, such as hospitals and physicians, may direct patients to other SNFs based on factors such as location, reputation, and relationships. This lack of customer loyalty limits ENSG's ability to command premium pricing or retain market share.
While ENSG's operational expertise and efficient scale provide a competitive advantage, the industry's regulatory landscape, reimbursement pressures, and low switching costs constrain the width of its moat. The company's ability to maintain and expand its moat will depend on its continued success in acquiring and turning around underperforming facilities, managing costs effectively, and adapting to evolving regulatory requirements.
Financial Health & Profitability
Ensign Group has demonstrated strong financial performance in recent years, characterized by robust revenue growth and improving profitability. The company's revenue has grown significantly, from $3.73 billion in FY2023 to $5.06 billion in FY2025, representing a compound annual growth rate (CAGR) of approximately 16.5%. This growth has been driven by a combination of acquisitions and organic expansion, reflecting ENSG's successful turnaround strategy and increasing demand for post-acute care services.
The company's gross margin has remained relatively stable, hovering around 20-21% over the past few years. However, operating margin has shown improvement, increasing from 6.8% in FY2023 to 8.4% in FY2025. This improvement reflects ENSG's ability to manage costs effectively and improve operational efficiency at its facilities. Net income has also increased substantially, from $209.85 million in FY2023 to $344.26 million in FY2025, indicating strong profitability growth.
However, ENSG's free cash flow (FCF) is negative at $-357.06 million. This is a significant concern, and likely due to the capital-intensive nature of their acquisition-based growth strategy. The company is investing heavily in acquiring and improving facilities, which requires significant upfront capital expenditures. While these investments are expected to generate future cash flows, the current negative FCF raises questions about the sustainability of the company's growth strategy.
Compared to the healthcare sector, ENSG exhibits superior profitability metrics. Its ROE of 14.6% significantly outperforms the sector average of -42.5%, indicating efficient utilization of equity. Operating and net margins are also substantially higher than the sector averages, reflecting ENSG's operational expertise and cost management capabilities. However, the company's gross margin is significantly lower than the sector average, suggesting that it may face challenges in controlling direct costs.
ENSG's balance sheet is characterized by a relatively high debt-to-equity (D/E) ratio of 6.00, compared to the sector average of 30.00. While this indicates a higher level of leverage, the company's strong profitability and cash flow generation provide some comfort. The current ratio of 1.42 suggests that ENSG has sufficient liquidity to meet its short-term obligations. The company's total cash balance of $443.67 million provides a buffer against unexpected expenses or downturns in the business.
Valuation Assessment
Ensign Group's valuation appears stretched relative to its peers and historical averages. The company's P/E ratio of 33.4x is significantly higher than the healthcare sector average of 24.3x, suggesting that investors are paying a premium for its growth prospects. Similarly, its EV/EBITDA multiple of 6.9x is slightly above the sector average of 6.4x, indicating that the company is relatively expensive on an enterprise value basis.
Given the company's strong revenue growth and profitability improvements, a premium valuation may be justified. However, the current valuation appears to fully reflect these positive factors, leaving limited room for further upside. The company's negative free cash flow is also a concern, as it suggests that the company may need to raise additional capital to fund its growth strategy. This could potentially dilute existing shareholders and negatively impact the stock price.
A discounted cash flow (DCF) analysis would be necessary to determine a more precise intrinsic value for ENSG. However, based on the available data, it appears that the stock is currently trading at or above its fair value. The company's high P/E ratio and negative free cash flow suggest that investors should exercise caution before investing in ENSG.
Compared to its historical valuation, ENSG's current multiples are elevated. The company's P/E ratio has historically traded in a range of 20-30x, suggesting that the current multiple is at the upper end of this range. Similarly, its EV/EBITDA multiple has typically been below 6x, indicating that the current multiple is relatively high. This suggests that the stock may be overvalued based on its historical performance.
While ENSG's strong growth and profitability warrant a premium valuation, the current multiples appear to be excessive. Investors should carefully consider the company's risks and uncertainties before investing in ENSG, as the stock may be vulnerable to a correction if its growth slows or its profitability declines.
Risk & Uncertainty
Ensign Group faces several specific risks that could negatively impact its business and financial performance. One of the most significant risks is the regulatory environment in the healthcare industry. The company is subject to extensive regulations at the federal, state, and local levels, including those related to licensing, certification, and reimbursement. Changes in these regulations could increase compliance costs, reduce reimbursement rates, and limit the company's ability to operate its facilities effectively.
Another key risk is competition within the skilled nursing facility (SNF) industry. ENSG competes with other SNF operators, hospitals, and home healthcare providers. Increased competition could lead to lower occupancy rates, reduced pricing power, and decreased profitability. The company's ability to attract and retain patients depends on its reputation for quality of care, service, and clinical outcomes. Any negative publicity or adverse events could damage its reputation and negatively impact its business.
The company's reliance on acquisitions for growth also introduces integration risks. Integrating acquired facilities into ENSG's operational model can be challenging and time-consuming. The company may encounter difficulties in implementing its systems, processes, and culture at acquired facilities. Failure to successfully integrate acquisitions could result in lower profitability and reduced returns on investment.
Reimbursement risk is also a significant concern. ENSG derives a substantial portion of its revenue from government payers, such as Medicare and Medicaid. Changes in reimbursement rates or payment policies could significantly impact the company's financial performance. The government may reduce reimbursement rates as part of efforts to control healthcare costs. The company's ability to negotiate favorable reimbursement rates with private payers is also critical to its profitability.
Finally, ENSG's relatively high debt-to-equity ratio exposes it to financial risk. The company's debt obligations require it to make regular interest and principal payments. A downturn in the business or an increase in interest rates could make it difficult for the company to meet its debt obligations. This could lead to financial distress or even bankruptcy.
Bulls Say / Bears Say
The Bull Case
BULL VIEWEnsign Group's proven turnaround strategy and decentralized management model will continue to drive strong revenue and earnings growth, exceeding market expectations.
BULL VIEWThe company's focus on higher-acuity patients and expansion into ancillary services will further diversify its revenue streams and enhance its competitive advantage, leading to higher margins.
BULL VIEWAs the aging population grows, the demand for post-acute care services will increase, benefiting Ensign Group and driving long-term shareholder value.
The Bear Case
BEAR VIEWEnsign Group's high valuation and negative free cash flow make it vulnerable to a correction, especially if growth slows or interest rates rise.
BEAR VIEWRegulatory changes and reimbursement pressures in the healthcare industry could significantly reduce Ensign Group's profitability and limit its growth potential.
BEAR VIEWThe company's aggressive acquisition strategy introduces integration risks and could lead to overpayment for assets, negatively impacting returns on investment.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score ENSG and 4,400+ other equities.
ENSIGN GROUP, INC exhibits a 142% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
6.0%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
20.4%
Sector: 71.5%
Operating Margin
Core business profitability
8.2%
Sector: -66.1%
Net Margin
Bottom-line profitability
6.9%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
Sector Avg Yield0.00%
Yield Delta—
Income Projection audit
A $10,000 investment would generate approximately $14 annually in dividends at the current trailing rate.
